No abstract

A panel of nurses was selected to conduct the test with different profiles (age, experience, and confidence with IT applications). Each nurse was asked to carry on some cycles of the therapy dispensing and to express evaluations, in a ranking from 1 to 5, on several parameters related to:. Tracking of all operations . Patient Safety . Ergonomics . Efficiency ResultsAbstract 5PSQ-021 Figure 1 Conclusion and Relevance The results show that the automatic system is prevailing over all target metrics, with particularly a high gap on safety and efficiency, thanks to the reduction of non-value-added activities such as manual drugs replenishment of the stocks within cabinets and carts, enabling what really matters: the Patient Care.This provides to the healthcare systems a new disruptive platform that makes the work of hospital staff easier, more efficient, reliable thus ensuring patient safety.

accounting for each patient, cycle and milligram of pembrolizumab administered. Results Forty-six patients (38 men and 8 women), with a median of 65 years old (range 39-77) were included. 26 patients (57%) received a weight based, 2 mg/kg dose (WD group). The median body weight was 73 kg in both groups (range 49-105). Overall response rate (complete/partial response) was 60% in the WD and 50% in the FD group. PFS was 13.24 months (CI95% 10-16.5) on average in the WD group and 13.7 months (CI95% 8.1-19.1) in the FD group. OS was 18.15 months (CI95% 14.3-22) in the WD group and 18.16 (CI95% 12.6-23.6) in the FD group. No significant differences were found in the log-rank test.Patients in the WD group received an average of 148 ± 27 mg of pembrolizumab for a median of 22 cycles; the FD group received 200 mg and a median of 41 cycles. Most patients (95%) received a lower dose than those in the FD group. On average, the total treatment cost per patient was reduced by 34% in the WD group. The estimated saved public expenditure was C ¼ 420852 in this pathology. Conclusion and RelevancePembrolizumab weight-based dosing was as effective as the fixed dose regime and reduced costs in patients with NSCLC.